The safety and efficacy of Hizentra self-infusions have been proven in patients age 2 and older.
Hizentra delivered low rates of infection in a 12-month study with zero serious infections that could potentially require hospitalization, like bacterial pneumonia, bacteremia/ septicemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess.
The same 12-month study found an average of 2.76 overall infections per subject-year.
People taking Hizentra missed about 2 days of work or school per year due to infections (2.06 days per person per year on average in clinical studies).
In a 12-month study of people taking Hizentra, there were no serious side effects related to treatment.
Two subjects withdrew from the study due to non-serious side effects. Please see full Important Safety Information below, including boxed warning.
The most common side effects in the clinical trials for Hizentra include redness, swelling, itching, and/or bruising at the infusion site; headache; chest, joint or back pain; diarrhea; tiredness; cough; rash; itching; fever, nausea, and vomiting. These are not the only side effects possible.
The only SCIg that has been providing protection against infection since 2010.